Our Team

Martin Godbout

Martin Godbout, O.C., PhD

Chair of the Board

Following a brief academic career at Université Laval in the early 90s, Martin Godbout was named President and General Manager of Société Innovatech Québec. In 1997, he pursued his career in the biopharmaceutical venture capital sector as Senior Vice President of BioCapital. In May 2000, he became the founding President and CEO of Genome Canada, which he led for nearly 10 years.

Officer of the Order of Canada, Mr. Godbout is currently Chair of the Board of AmorChem-1, BioContact, BIOQuebec and Genome Quebec. He is also an independent Board member of the following organizations: AngioChem, Fonds de recherche du Québec - Santé, P3G, Ataxia Charlevoix-Saguenay Fondation, Leucodystrophies Fondation and Baie-Saint-Paul Hospital Fondation.

Mr. Godbout holds a PhD in Physiology and Molecular Endocrinology from Université Laval and completed a postdoctoral training in neuromolecular biology at the Scripps Research Institute, in San Diego. In 2016, he was named Grand Diplômé from Université Laval.

Isabelle Bouffard

Isabelle Bouffard holds a Bachelor of Agricultural Economics from McGill University. Since 2005, she has worked for the Research and Agricultural Policy department of the Union des producteurs agricoles (UPA). In 2016, she was appointed director of the department.

Prior to this, she worked as economic advisor and subsequently as manager of the economics and commerce team. Over the years, she has coordinated efforts in a variety of areas, including commerce, economics, energy and municipal taxation pertaining to agriculture. In this capacity, she has participated in the work of many provincial and national committees.

Me Jean Brunet

Me Jean Brunet

Secretary of the Board

Managing Partner of Stein Monast L.L.P.

Jean Brunet specializes in corporate and commercial law, including the negotiation and drafting of business purchase and sales agreements, mergers, corporate reorganizations and shareholders’ agreements. Mr. Brunet also practises intellectual property law, including negotiating and drafting research contracts, distribution agreements, and licence and technology transfer agreements, mainly in the sectors of pharmaceuticals, genomics, proteomics, bioinformatics and biotechnology.

In addition, Mr. Brunet acts as legal counsel and corporate secretary for various companies, particularly in the areas of biotechnology, genomics and proteomics, including active involvement on the boards of Genome Canada and Génome Québec. His duties include advising these companies on corporate governance policies and compliance matters. Mr. Brunet is one of the founders and directors of BioContact, an annual biotechnology symposium.

Daniel Coderre

Daniel Coderre, PhD

President and CEO, Génome Québec

Since September 2016, Daniel Coderre is President and CEO of Génome Québec, an organization supporting scientific and strategic development of genomics in Québec.

A certified corporate director (ASC - Administrateur de sociétés certifié) Mr. Coderre has a proven track record in public administration.

Daniel Coderre served as Rector of the Institut national de la recherche scientifique (INRS) from 2009 to 2016, where he acquired solid expertise in public administration and built a wide network of partners.

He holds a doctorate in biology from the Université de Sherbrooke. He began his career in 1982 as a biology professor at UQAM, where he supervised 85 masters and doctoral students and published nearly 100 scientific publications. He also served as Dean of the Faculty of Science and Vice-Rector of Research before being appointed Vice-President of Academic Affairs and Research from 2004 to 2009 and in 2009, as its Interim President.

He has held positions on close to twenty committees, boards of directors, scientific, government and international committees and various commissions on science, technology and innovation.

Jean-François Ethier

Jean-François Ethier

MD, CM, PhD, FRCPC

Clinical Researcher and Assistant ProfessorDepartment of medicine, Université de Sherbrooke

Professor Jean-François Ethier is a clinical researcher and assistant professor at the Department of Medicine of Université de Sherbrooke. He also works as a researcher at the INSERM UMRS-1138 in Paris in addition to coleading the Groupe de recherche interdisciplinaire en informatique de la santé (GRIIS.ca).

He holds a Bachelor of Internal Medicine from McGill University and a PhD in Epidemiology and Biomedical Information Science from Université Paris VI (Pierre and Marie Curie).

Pr. Ethier’s research focuses on ways to place patients at the centre of research and decision support systems (learning healthcare system). More specifically, he develops semantic interoperability frameworks between health and research systems, structures biomedical data warehouses and develops formal knowledge-based models to facilitate the uniform access to clinical, genomics, administrative and quantified self (lifelogging) data.

Marc LePage

Marc LePage

Observer

President and CEO, Genome Canada

Marc LePage was appointed President and CEO of Genome Canada December 2015. Before this, he served as President and CEO of Génome Québec since December 2011, where he led a major increase in research activity and enhanced focus on the development of genomic applications within priority sectors within the province.

He brings a wealth of experience in the innovation sector and venture capital, in addition to a broad network of international contacts.

He is an expert in international partnerships and previously served as Special Advisor, Climate Change and Energy for the Embassy of Canada in Washington, D.C. and worked as Consul General at the Canadian Consulate in San Francisco/Silicon Valley.

Marc LePage was also one of the pioneers behind the founding of Genome Canada in 2000. During his tenure as Executive Vice-President of Corporate Development, he made a significant contribution to the development of genomics in Canada.

From 1994 to 2000, he worked as Director of Business Development for the Medical Research Council, where he was in charge of building international partnerships with the pharmaceutical industry, venture capital and foundations.

Marc LePage is a member of the Board and the Governance Committee of the Quebec Network for Personalized Health Care. He also sits on the Board of Canada World Youth.

Paul Lepage

Paul Lepage, B.Eng., MBA, Dr. h.c.

President, TELUS Health and Payment SolutionsChair, TELUS Ventures

Paul spearheads TELUS Health’s mission to harness the power of information technologies for better health care. His mission focuses on creating and integrating digital tools to help health providers and patients capture and share information in a rapid, secure and streamlined and user-friendly manner in order to support changes to the health care system aimed at improving its efficiency and empowering patients. In his commitment to expanding TELUS Health’s position as the leading organization in healthcare IT in Canada, Paul draws on more than 30 years of experience in the health telecommunications and information technology sectors.

Before joining TELUS Health in 2009, he was the President and CEO of MediSolution Ltd., a leader in the North American IT industry. Prior to this, he held various leadership roles, including Chief Marketing Officer, Chief Operating Officer and head of Global Sales for several major technology companies. Since 2016, Paul has also managed TELUS Ventures, the venture capital arm of TELUS. The branch specializes in strategic investments in market opportunities whose innovations have the potential to accelerate the growth of TELUS, particularly in the area of health.

Paul has a Master of Business Administration from Concordia University and a Bachelor of Engineering from École Polytechnique de Montréal. He serves on the board of directors for Montréal InVivo and TOHealth!as well as on the advisory board of Edmonton: Canada’s Health City in Alberta. He previously sat on the board of directors of Get Real Health in the United States, the Quebec Technology Association (QTA), IBWave, Nova Expertise Solutions, Medisolution and Blue Streak Technology, as well as serving on the Montreal Community Board of TELUS. Paul has also leveraged his expertise on committees for organizations such as CEFRIO, the Sandbox Project, the Ivey Centre for Health Innovation and the Juvenile Diabetes Research Foundation, where he also acted as honorary president and national campaign manager for several years. He has received the ICD.D certification granted by the Institute of Corporate Directors.

Sylvain Moineau

Sylvain Moineau, PhD, FRSC

Full ProfessorDépartement de biochimie, de microbiologie et de bio-informatiqueUniversité Laval

Professor Sylvain Moineau completed a Bachelor of Microbiology at Université Laval in 1987. He pursued his academic career at the same university and, in 1993, earned a PhD in Food Science. During his PhD, he also spent 18 months at North Carolina State University. He then pursued industrial postdoctoral work with Unilever, the Florida-based multinational.

In 1996, he returned to Université Laval as Assistant Professor in microbiology, where his research team studies the biology of phages and phage-resistance mechanisms, including work on CRISPR-Cas systems. In 2005, he earned his full professorship and, since 2011, he holds the Canada Research Chair in Bacteriophages.

Since 2002, he has also served as the curator of the Félix d’Hérelle Reference Centre for Bacterial Viruses, the world’s largest collection of phages (www.phage.ulaval.ca).

Over the years, Professor Moineau has won many teaching and research awards. In 2017, for example, he was presented with the John C. Polanyi Award by the NSERC. The award honours research done in Canada that has led to an outstanding advance in natural science or engineering. Recently, he was elected Fellow of the Academy of Science of The Royal Society of Canada. In 2016, he received the Flavelle Medal from the Royal Society of Canada for his exceptional contribution to biological science over the last decade. For three consecutive years (2014, 2015, 2016), Professor Moineau has also been on the Thomas Reuters list of the most cited researchers in the microbiology category.

Marie-Lucie Morin

Marie-Lucie Morin

Marie-Lucie Morin took up her functions as Executive Director for Canada, Ireland and the Caribbean at the World Bank in November 2010. She was appointed National Security Advisor to the Prime Minister of Canada and Associate Secretary to the Cabinet in November 2008. From April 2006 to November 2008, she served as Deputy Minister of International Trade and from December 2003 to April 2006, as Associate Deputy Minister of Foreign Affairs. Prior to this appointment, she held the post of Assistant Deputy Minister, International Business, and Chief Trade Commissioner.

Mrs. Morin has extensive experience abroad, acquired during postings to San Francisco, Jakarta, London and Moscow. In 1997, she was appointed as Canada's Ambassador to the Kingdom of Norway with concurrent accreditation to the Republic of Iceland, a position she held until 2001.

From its creation in 2007 until 2009, Mrs. Morin was a member of the Science, Technology and Innovation Council of Canada (STIC). She also served on the Board of the Canadian Commercial Corporation. Since early 2012, she is a member of the Advisory Panel on Open Government presided by the President of the Treasury Board of Canada.

Mrs. Morin was awarded the Governor General’s 125th Anniversary of the Confederation of Canada Medal in 1992. In 2011, she received the Association of Professional Executives of the Public Service of Canada’s (APEX) Global Public Servant Award and was made “Chevalier de la Légion d’Honneur” (France) in 2012.Mrs. Morin was born in Sherbrooke, Quebec, in 1957. She graduated with her Licentiate in Laws from the Université de Sherbrooke and in 1980, she was admitted to the Barreau du Québec.

Mrs. Morin is married to Nicolas Temnikov; they have one daughter and three sons.